These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21431505)

  • 21. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
    Kröger N; Sockel K; Wolschke C; Bethge W; Schlenk RF; Wolf D; Stadler M; Kobbe G; Wulf G; Bug G; Schäfer-Eckart K; Scheid C; Nolte F; Krönke J; Stelljes M; Beelen D; Heinzelmann M; Haase D; Buchner H; Bleckert G; Giagounidis A; Platzbecker U
    J Clin Oncol; 2021 Oct; 39(30):3318-3327. PubMed ID: 34283629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
    Falantes J; Delgado RG; Calderón-Cabrera C; Márquez-Malaver FJ; Valcarcel D; de Miguel D; Bailén A; Bargay J; Bernal T; González-Porras JR; Tormo M; Ramos F; Andreu R; Xicoy B; Nomdedeu B; Brunet S; Sánchez J; Jurado AF; Bonanad S; Pérez-Simón JA; Sanz G;
    Leuk Res; 2015 Jan; 39(1):52-7. PubMed ID: 25487012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
    Ofran Y; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Merkel D
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e95-9. PubMed ID: 25819366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
    Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
    J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing patients with low-risk MDS.
    Sekeres M; Cosgrove D; Falco A
    Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
    Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
    Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.
    Lai SW; Huang TC; Ye RH; Wu YY
    Eur J Haematol; 2015 Mar; 94(3):273-6. PubMed ID: 24797511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
    Haas PS; Wijermans P; Verhoef G; Lübbert M
    Leuk Res; 2006 Mar; 30(3):338-42. PubMed ID: 16162357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
    Morita Y; Maeda Y; Yamaguchi T; Urase F; Kawata S; Hanamoto H; Tsubaki K; Ishikawa J; Shibayama H; Matsumura I; Matsuda M
    Cancer Sci; 2018 Oct; 109(10):3209-3215. PubMed ID: 30007103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
    Douvali E; Papoutselis M; Vassilakopoulos TP; Papadopoulos V; Spanoudakis E; Tsatalas C; Kotsianidis I
    Leuk Res; 2013 Aug; 37(8):889-93. PubMed ID: 23726719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
    Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
    Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
    Papoutselis M; Douvali E; Papadopoulos V; Spanoudakis E; Margaritis D; Tsatalas C; Kotsianidis I
    Leuk Res; 2014 Feb; 38(2):161-5. PubMed ID: 24239174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.